Tryngolza (olezarsen) has been FDA-approved as an adjunct to diet for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS), a condition that can lead to life-threatening acute pancreatitis. It significantly reduces triglyceride levels and the risk of acute pancreatitis when combined with a low-fat diet. The approval was based on a successful phase 3 clinical trial showing a 57% reduction in triglycerides over 12 months and a decrease in acute pancreatitis events. Tryngolza can be self-administered once monthly and has a favorable safety profile. This treatment option is now available for adults with FCS, marking a significant advancement in managing the condition.
Source link
FDA approves Tryngolza as adjunct to diet for familial chylomicronemia syndrome
